
FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.
Phase II of FDA's GMP modernization plan may involve revising regulations to fit new policies and inspection and review programs.
about 22 years ago
Still Waiting for Answersabout 22 years ago
Comparing and Contrasting Barrier Isolator Decontamination Systemsabout 22 years ago
November 2004about 22 years ago
In the Spotlight-November 2004about 22 years ago
Searching for a Viable Business Model




